Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.

Article  CAS  PubMed  Google Scholar 

Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.

Article  CAS  PubMed  Google Scholar 

Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014–26.

Article  CAS  PubMed  Google Scholar 

Andre T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383–95.

Article  CAS  PubMed  Google Scholar 

Rocha Lima CMS, Ou F-S, Caron WP, et al. Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab monotherapy versus mFOLFOX6/bevacizumab/atezolizumab in the first-line treatment of patients with dMMR/MSI-H mCRC (NRG-GI004/SWOG-S1610). J Clin Oncol. 2026;44(suppl 3):14.

Article  Google Scholar 

Andre T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277–84.

Article  CAS  PubMed  Google Scholar 

Vikas P, Messersmith H, Compton C, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol. 2023;41:1943–8.

Article  CAS  PubMed  Google Scholar 

Cohen R, Hain E, Buhard O, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 2019;5:551–5.

Article  PubMed  PubMed Central  Google Scholar 

Le DT, Diaz LA Jr, Kim TW, et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023;186:185–95.

Lenz HJ, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161–70.

Article  CAS  PubMed  Google Scholar 

Pietrantonio F, Morano F, Lonardi S, Cremolini C. Systemic treatment of mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition. ESMO Open. 2024;9:103584.

Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline. J Clin Oncol. 2018;36:1714–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–38.

Article  CAS  PubMed  Google Scholar 

Cauchin E, Cohen R, Vernerey D, et al. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study. ESMO Open. 2023;8:101622.

Google Scholar 

Cantini L, Tabbò F, Mentrasti G, et al. Exploring resistance to immune checkpoint inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer. Cancer Treat Rev. 2026;133:102887.

Google Scholar 

Mazzoli G, Cohen R, Lonardi S, et al. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022;172:171–81.

Article  CAS  PubMed  Google Scholar 

Cohen R, Lefebvre C, De La Fouchardiere C, et al. Patterns of progressive disease in patients with MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors: the ImmunoMSI cohort. Eur J Cancer. 2025;218:115289.

Google Scholar 

Gallois C, Ambrosini M, Lonardi S, et al. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2025;227:115645.

Article  CAS  PubMed  Google Scholar 

Kopetz S, Elez E, Tabernero J, et al. SEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and MSI-H/dMMR metastatic colorectal cancer. J Clin Oncol. 2022;40(suppl 16):TPS3634.

Article  Google Scholar 

Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31:901–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ESMO Living guideline. metastatic colorectal cancer: first-line therapy for RAS-mut, BRAF-mut, or dMMR/MSI-H disease. European Society for Medical Oncology. Updated 2025. Accessed April 2, 2026.

ClinicalTrials.gov. MK-1308A-008: pembrolizumab plus quavonlimab vs pembrolizumab for first-line dMMR/MSI-H mCRC. NCT04895722. Accessed April 2, 2026.

Sinicrope FA, Ou F-S, Arnold D et al. ATOMIC: atezolizumab plus FOLFOX as adjuvant therapy for stage III dMMR colon cancer. J Clin Oncol. 2025;43(suppl 16)[abstract LBA3500].